Oxford Biomedica reports 36% decline in revenues for 2023
LONDON: Oxford Biomedica plc, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has released its preliminary financial results for the year ending December 31, 2023. Despite a challenging year, the Group has maintained stable core business…